News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tivorsan Pharmaceuticals, Inc.' Biglycan Protein Opens Unique Path for Preserving Muscle Function in Duchenne Muscular Dystrophy



12/28/2010 8:52:28 AM

PROVIDENCE, R.I.--(BUSINESS WIRE)--A novel therapy under development by Tivorsan Pharmaceuticals demonstrated reduction of muscle pathology and improved muscle function in a mouse model of Duchenne Muscular Dystrophy (DMD). The company is actively working towards human clinical studies with a proprietary form of the natural biglycan protein, which appears to have a unique mechanism of action that may apply to all genetic forms of DMD.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES